Skip to main content
SpringerLink
Log in

CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

An Erratum to this article was published on 31 July 2014

Abstract

Rationale

Modulation of the endocannabinoid system has been found to interfere with opiate withdrawal. The potential of activation and blockade of the endocannabinoid system to prevent the aversive-affective state of naloxone-precipitated morphine withdrawal (MWD) was investigated in a one-trial conditioned place aversion (CPA) paradigm.

Objective

CPA provides a sensitive measure of the motivational effects of acute MWD. The potential of the fatty acid amide hydrolase (FAAH) inhibitors, URB597 and PF-3845, the CB1 antagonist/inverse agonist, AM251, and the neutral CB1 antagonists, AM4113 and AM6527 (oral), to interfere with establishment of a MWD-induced CPA was investigated. As well, the potential of AM251 and AM4113 to interfere with reinstatement of a previously established MWD-induced CPA was investigated.

Materials and methods

Using a one-trial place conditioning paradigm, rats were administered naloxone (1 mg/kg, subcutaneous (sc)) 24 h after receiving a high dose of morphine (20 mg/kg, sc) and were placed on the conditioning floor. To determine the effect of each pretreatment drug on the establishment of the MWD-induced CPA, URB597 (0.3 mg/kg, intraperitoneally (ip)), PF-3845 (10 mg/kg, ip), AM251 (1 or 2.5 mg/kg, ip), AM4113 (1 or 2.5 mg/kg, ip), and AM6527 (5 mg/kg, oral) were administered prior to conditioning.

Results

AM251 (2.5, but not 1 mg/k), AM4113, and AM6527, but not URB597 or PF-3845, interfered with the establishment of the MWD-induced CPA. AM251 and AM4113 did not prevent reinstatement of the CPA.

Conclusions

Neutral antagonism of the CB1 receptor reduces the aversive affective properties of morphine withdrawal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S, Stiff C, Kamtekar S, Bhattacharya K, Zhang Y, Swaney S, Van Becelaere K, Stevens RC, Cravatt BF (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16(4):411–420

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Bergman J, Delatte MS, Paronis CA, Vemuri K, Thakur GA, Makriyannis A (2008) Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol Behav 93:666–670

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Bhargava HN (1976) Inhibition of naloxone-induced withdrawal in morphine dependent mice by 1-trans-∆9-tetrahydrocannabinol. Eur J Pharmacol 36(1):259–262

    Article  PubMed  CAS  Google Scholar 

  • Bozarth MA, Wise RA (1984) Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 224:516–517

    Article  PubMed  CAS  Google Scholar 

  • Caille S, Parsons LH (2003) SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci 18:3145–3149

    Article  PubMed  Google Scholar 

  • Chambers AP, Vemuri KV, Peng Y, Wood JT, Olszewska T, Pittman QJ, Makriyannis A, Sharkey KA (2007) A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293:R2185–R2193

    Article  PubMed  CAS  Google Scholar 

  • Chaperon F, Soubrie P, Puech AJ, Thiebot MH (1998) Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berlin) 135:324–332

    Article  CAS  Google Scholar 

  • Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706–1713

    Article  PubMed  CAS  Google Scholar 

  • De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmer ANM (2003) Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 168:164–169

    Article  PubMed  Google Scholar 

  • Fattore L, Spano MS, Cossu G, Deiana S, Fratta W (2003) Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 17:1723–1726

    Article  PubMed  CAS  Google Scholar 

  • Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3- carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313(1):352–358

    Article  PubMed  CAS  Google Scholar 

  • Ford CP, Mark GP, Williams JT (2006) Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci 26:2788–2797

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Frenois F, Cador M, Caillé S, Stinus L, Le Moine C (2002) Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 16:1377–1389

    Article  PubMed  Google Scholar 

  • Frenois F, Stinus L, Di Blasi F, Cador M, Le Moine C (2005) A specific limbic circuit underlies opiate withdrawal memories. J Neurosci 25(6):1366–1374

    Article  PubMed  CAS  Google Scholar 

  • Gobbi G, Bambico FR, Manqieri R, Bortalato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102:18620–18625

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Gracy NK, Dankiewicz LA, Koob GF (2001) Opiate withdrawal-induced fos immunoreactivity in the rat extended amygdala parallels the development of conditioned place aversion. Neuropsychopharmacology 24:152–160

    Article  PubMed  CAS  Google Scholar 

  • Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA (1990) Acute opioid physical dependence in humans: effect of naloxone at 6 and 24 hr postmorphine. Pharmacol Biochem Behav 36:393–399

    Article  PubMed  CAS  Google Scholar 

  • Hou YY, Lu B, Li M, Liu Y, Chen J, Chi ZQ, Liu JG (2009) Involvement of actin rearrangement within the amygdala and the dorsal hippocampus in aversive memories of drug withdrawal in acute morphine-dependent rats. J Neurosci 29(39):12244–12254

    Article  PubMed  CAS  Google Scholar 

  • Ishida S, Shimosaka R, Kawasaki Y, Jin C, Kitamura Y, Araki H, Sendo T, Gomita Y (2008) Involvement of the amygdala on place aversion induced by naloxone in single-dose morphine-treated rats. Yakugaku Zasshi 128(3):395–403

  • Jin C, Araki H, Nagata M, Suemaru K, Shibata K, Kawasaki H, Hamamura T, Gomita Y (2004) Withdrawal-induced c-Fos expression in the rat centromedial amygdala 24 h following a single morphine exposure. Psychopharmacology 175:428–435

    PubMed  CAS  Google Scholar 

  • Jin C, Araki H, Nagata M, Shimosaka R, Shibata K, Suemaru K, Kawasaki H, Gomita Y (2005) Expression of c-Fos in the rat central amygdala accompanies the acquisition but not expression of conditioned place aversion induced by withdrawal from acute morphine dependence. Behav Brain Res 161:107–112

    Article  PubMed  CAS  Google Scholar 

  • Johnson SW, North RA (1992) Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12:483–488

    PubMed  CAS  Google Scholar 

  • June HL, Stitzer ML, Cone E (1995) Acute physical dependence: time course and relation to human plasma morphine concentrations. Clin Pharmacol Ther 57:270–280

    Article  PubMed  CAS  Google Scholar 

  • Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana GL, Calignano A, Guistino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9(1):76–81

    Article  PubMed  CAS  Google Scholar 

  • Koob GF (2009) Dynamics of neuronal circuits in addiction: reward, antireward, and emotional memory. Pharmacopsychiatry 42(suppl 1):S32–S41

    Article  PubMed  PubMed Central  Google Scholar 

  • Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58

    Article  PubMed  CAS  Google Scholar 

  • Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24(2):97–129

    Article  PubMed  CAS  Google Scholar 

  • Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401–404

    Article  PubMed  CAS  Google Scholar 

  • Li Y, Liu X, Chen H, Deng H, Xiang X, Chen H, Hao W (2007) Development, extinction and reinstatement of morphine withdrawal-induced conditioned place aversion in rats. Addict Biol 12:470–477

    Article  PubMed  CAS  Google Scholar 

  • Lichtman AH, Sheikh SM, Loh HH, Martin BR (2001) Opioid and cannabinoid modulation of precipitated withdrawal in ∆9-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 298:1007–1014

    PubMed  CAS  Google Scholar 

  • Madhavan A, Bonci A, Whistler JL (2010) Opioid-induced GABA potentiation after chronic morphine attenuates the rewarding effects of opioids in the ventral tegmental area. J Neurosci 30:14029–14035

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Maldonado R, Stinus L, Gold LH, Koob GF (1992) Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 261:669–677

    PubMed  CAS  Google Scholar 

  • Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29(4):225–232

    Article  PubMed  CAS  Google Scholar 

  • Manwell LA, Satvat E, Lang ST, Allen CP, Leri F, Parker LA (2009) FAAH inhibitor, URB- 597, promotes extinction and CB1 antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats. Pharmacol Biochem Behav 94:154–162

    Article  PubMed  CAS  Google Scholar 

  • Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, Roques BP, Noble F (2001) Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 132(8):1809–1816

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • McCallum AL, Limebeer CL, Parker LA (2010) Reducing endocannabinoid metabolism with the fatty acid amide hydrolase inhibitor, URB597, fails to modify reinstatement of morphine- induced conditioned floor preference and naloxone-precipitated morphine withdrawal- induced conditioned floor avoidance. Pharmacol Biochem Behav 96:496–500

    Article  PubMed  CAS  Google Scholar 

  • McDonald RV, Parker LA, Siegel S (1997) Conditioned sucrose aversions produced by naloxone-precipitated withdrawal from acutely administered morphine. Pharmacol Biochem Behav 58:1003–1008

    Article  PubMed  CAS  Google Scholar 

  • Meyer DR, Sparber SB (1977) Evidence of possible opiate dependence during the behavioral depressant action of a single dose of morphine. Life Sci 73:1087–1094

    Article  Google Scholar 

  • Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gómez R, del Arco I, Villanúa MA, Maldonado R, Koob GF, Rodríguez de Fonseca F (2001) Functional interaction between opioid and cannabinoid receptors in drug self- administration. J Neurosci 21:5344–5350

    PubMed  CAS  Google Scholar 

  • Nestler EJ, Aghajanian GK (1997) Molecular and cellular basis of addiction. Science 278:58–63

    Article  PubMed  CAS  Google Scholar 

  • Parker LA, Joshi A (1998) Naloxone-precipitated morphine withdrawal induced place aversions: effects of naloxone at 24 hours postmorphine. Pharmacol Biochem Behav 61(3):331–333

    Article  PubMed  CAS  Google Scholar 

  • Parker LA, Cyr JA, Santi AN, Burton PD (2002) The aversive properties of acute morphine dependence persist 48 h after a single exposure to morphine: evaluation by taste and place conditioning. Pharmacol Biochem Behav 7287–7292

  • Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R (2004) Effect of low doses of Δ9- tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology 175:360–366

    Article  PubMed  CAS  Google Scholar 

  • Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, Long JZ, Nomura DK, Sim-Selley LJ, Cravatt BF, Akbarali HI, Lichtman AH (2011) Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 339:173–186

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Rubino T, Massi P, Vigano’ D, Fuzio D, Parolaro D (2000) Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci 66(22):2213–2219

    Article  PubMed  CAS  Google Scholar 

  • Schoffelmeer ANM, Hogenboom F, Wardeh G, De Vries TJ (2006) Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51:773–781

    Article  PubMed  CAS  Google Scholar 

  • Shoji Y, Delfs J, Williams JT (1999) Presynaptic inhibition of GABA(B)-mediated synaptic potentials in the ventral tegmental area during morphine withdrawal. J Neurosci 19:2347–2355

    PubMed  CAS  Google Scholar 

  • Singh ME, Verty AN, McGregor IS, Mallet PE (2004) A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. Brain Res 1026:244–253

    Article  PubMed  CAS  Google Scholar 

  • Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, Markus EJ, Vemuri VK, Makriyannis A, Salamone JD (2010) Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 20:112–122

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003) The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3- carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self- administration in rats. J Pharmacol Exp Ther 306:93–102

    Article  PubMed  CAS  Google Scholar 

  • Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR (2005) Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 30:2046–2057

    Article  PubMed  CAS  Google Scholar 

  • Stinus L, Le Moal M, Koob GF (1990) Nucleus accumbens and the amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 37(3):767–773

    Article  PubMed  CAS  Google Scholar 

  • Trang T, Ma W, Chabot JG, Quirion R, Jhamandas K (2006) Spinal modulation of calcitonin gene-related peptide by endocannabinoids in the development of opioid physical dependence. Pain 126:256–271

    Article  PubMed  CAS  Google Scholar 

  • Valverde O, Tzavara E, Hanoune J, Roques BP, Maldonado R (1996) Protein kinases in the rat nucleus accumbens are involved in the aversive component of opiate Withdrawal. Eur J Neurosci 8:2671–2678

    Article  PubMed  CAS  Google Scholar 

  • Vela G, Ruiz-Gayo M, Fuentes JA (1995) Anandamide decreases naloxone precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34(6):665–668

    Article  PubMed  CAS  Google Scholar 

  • Watanabe T, Yamamoto R, Maeda A, Nakagawa T, Minami M, Satoh M (2002) Effects of excitotoxic lesions of the central or basolateral nucleus of the amygdala on naloxone- precipitated withdrawal-induced conditioned place aversion in morphine-dependent rats. Brain Res 958:423–428

    Article  PubMed  CAS  Google Scholar 

  • Wei E, Loh HH, Way EL (1972) Brain sites of precipitated abstinence in morphine dependent rats. J. Pharmacol Exp Ther 185:108–115

    Google Scholar 

  • Wei E, Loh HH, Way EL (1973) Neuroanatomical correlates of wet shake behavior in the rat. Life Sci 12(Part II):489–496

    Article  CAS  Google Scholar 

  • Xu W, Li YH, Tan BP, Luo XJ, Xiao L, Zheng XG, Yang XY, Sui N (2012) Inhibition of the acquisition of conditioned place aversion by dopaminergic lesions of the central nucleus of the amygdala in morphine-treated rats. Physiol Res 61:437–442

    PubMed  CAS  Google Scholar 

  • Yamaguchi T, Hagiwara Y, Tanaka H, Sugiura T, Waku K, Shoyama Y, Watanabe S, Yamamoto T (2001) Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 909:121–126

    Article  PubMed  CAS  Google Scholar 

  • Zarrindast MR, Sarahroodi S, Arzi A, Khodayar MJ, Taheri-Shalmani S, Rezayof A (2008) Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system. Behav Pharmacol 19:716–723

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank Dr. Roger Pertwee, University of Aberdeen, for helpful discussions about the data presented in the manuscript. KLW was supported by a CGS Scholarship from NSERC. The research was supported by research grants to LAP from NSERC (92057) and to A. Makriyannis from NIH.

Author information

Authors and Affiliations

  1. Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G 2W1, Canada

    Kiri L. Wills, Alana Kalmar, Alan Lee, Cheryl L. Limebeer & Linda A. Parker

  2. Center for Drug Discovery, Northeastern University, Boston, MA, USA

    Kiran Vemuri & Alexandros Makriyannis

Authors
  1. Kiri L. Wills
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kiran Vemuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alana Kalmar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alan Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cheryl L. Limebeer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexandros Makriyannis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Linda A. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Linda A. Parker.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wills, K.L., Vemuri, K., Kalmar, A. et al. CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats. Psychopharmacology 231, 4291–4300 (2014). https://doi.org/10.1007/s00213-014-3575-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-014-3575-5

Keywords

Search

Navigation